0001127602-24-014456.txt : 20240507
0001127602-24-014456.hdr.sgml : 20240507
20240507164844
ACCESSION NUMBER: 0001127602-24-014456
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240503
FILED AS OF DATE: 20240507
DATE AS OF CHANGE: 20240507
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NABEL ELIZABETH G
CENTRAL INDEX KEY: 0001619929
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 24922837
MAIL ADDRESS:
STREET 1: BRIGHAM AND WOMEN'S HOSPITAL
STREET 2: 75 FRANCIS ST
CITY: BOSTON
STATE: MA
ZIP: 02115
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 325 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 325 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-05-03
0001682852
Moderna, Inc.
MRNA
0001619929
NABEL ELIZABETH G
C/O MODERNA, INC.
325 BINNEY STREET
CAMBRIDGE
MA
02142
1
0
Common Stock
2024-05-03
4
M
0
732
A
2105
D
Restricted Stock Units
2024-05-03
4
M
0
732
0
D
Common Stock
732
0
D
Stock Option (Right to Buy)
122.13
2024-05-06
4
A
0
5668
0
A
2034-05-06
Common Stock
5668
5668
D
Restricted Stock Units
2024-05-06
4
A
0
979
0
A
Common Stock
979
979
D
Restricted stock units convert into common stock on a one-for-one basis.
The shares subject to this restricted stock unit award vested in full on May 3, 2024.
This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
/s/ Brian Sandstrom, as Attorney-in-Fact
2024-05-07